BPC-157 Arginate

What it is

The arginine salt form of BPC-157, a synthetic pentadecapeptide derived from a protein found in human gastric juice. The di-L-arginine salt (2 mol arginine per mol peptide) was developed and patented by the University of Zagreb group (WO2014142764A1) specifically for improved gastric stability and oral bioavailability compared to the acetate and free-base forms. Patent data claims significantly enhanced oral stability at pH 7.40, though no peer-reviewed human pharmacokinetic study has independently verified the comparative bioavailability claims. Standard BPC-157 (acetate salt, typically injected subcutaneously) exists as a separate entry in this database. The arginate form is discussed primarily in the context of oral capsule delivery for gastrointestinal applications.

Community-reported ranges

Oral dose ranges sourced from community forums and supplement vendor labeling. Oral stability claims derive from WIPO patent WO2014142764A1 (Sikiric et al.); no independent peer-reviewed verification exists. Not dosing guidance.

Frequently discussed alongside

Based on community forum discussions. Not a recommendation to combine compounds.

Published research

BPC-157's preclinical dataset spans 100+ animal studies over 30 years showing positive healing effects in tendon, ligament, muscle, bone, GI tract, liver, heart, brain, and spinal cord models. No acute lethal dose (LD1) has been identified. However, human evidence is critically thin: a registered Phase 1 trial (NCT02637284) was cancelled, early Croatian IBD trials were never fully published in major journals, and a 2025 IV safety pilot included only 2 subjects. Regarding the arginate salt specifically: the WO2014142764A1 patent claims superior gastric stability and oral bioavailability versus the acetate form, but no peer-reviewed study has compared the two salt forms in any species. The '7-fold oral bioavailability' claim originates from patent documents and vendor marketing only. The arginate form distinction exists at the patent and commercial level, not in the published scientific literature.

Reported side effects

From community self-reports. Not from controlled studies.

Community users report minimal side effects: occasional mild GI discomfort, headache, and transient fatigue. Systematic safety data in humans does not exist for either salt form. The primary theoretical concern is angiogenesis-driven tumor promotion — BPC-157 robustly promotes VEGFR2-mediated blood vessel formation, raising questions about use in individuals with active or occult malignancies. No direct evidence of tumor promotion exists in animal studies, but many practitioners contraindicate it in patients with cancer history.

Regulatory status